Clopidogrel Versus Aspirin Monotherapy in High-Risk Patients after Percutaneous Coronary Intervention (SMART-CHOICE 3): A Randomised, Open-Label, Multicentre Trial

Ki Hong Choi(Samsung Medical Center), anon Investigators, Danbee Kang(Samsung Medical Center), Kyeong Ho Yun(Wonkwang University Hospital), Hyeon‐Cheol Gwon(Samsung Medical Center), Kiyuk Chang(St. Mary's Hospital), Joon‐Hyung Doh(Inje University Ilsan Paik Hospital), Jang Hyun Cho, Jeong Hoon Yang(Samsung Medical Center), Ung Kim(Yeungnam University Medical Center), Doo Soo Jeon(Catholic University of Korea), Weon Kim(Kyung Hee University), Young Bin Song(Samsung Medical Center), Cheol Whan Lee(Ulsan College), Yong Hwan Park(Changwon National University), Han Cheol Lee(Pusan National University Hospital), Seung Hwan Han(Deleted Institution), Sung Gyun Ahn(Lodestar Research Corporation (United States)), Byung Ryul Cho(Kangwon National University), Chan Joon Kim(The Catholic University of Korea Uijeongbu St. Mary's Hospital), Seung‐Woon Rha, Taek Kyu Park(Samsung Medical Center), Jin‐Ok Jeong(Chungnam National University Hospital), Mahn‐Won Park(The Catholic University of Korea Daejeon St. Mary's Hospital), Jang‐Whan Bae(Chungbuk National University), Sung‐Ho Her(St. Mary's Hospital), Jong‐Young Lee(Ulsan College), Soo‐Youn Lee(Sungkyunkwan University), Seung-Hyuk Choi(Samsung Medical Center), Hyun‐Jong Lee, Jin Bae Lee(Daegu Catholic University Medical Center), Young Joon Hong(Chonnam National University Hospital), Joo-Yong Hahn(Samsung Medical Center), Hee-Yeol Kim(The Catholic University of Korea Bucheon St. Mary's Hospital), Doo‐Il Kim(Inje University Haeundae Paik Hospital), Joo Myung Lee(Samsung Medical Center)
SSRN Electronic Journal
January 1, 2025
Cited by 0


Related Papers